Safety of closed-loop therapy during reduction or omission of meal boluses in adolescents with type 1 diabetes: A randomized clinical trial

Diabetes, Obesity and Metabolism

Volumn 16, Issue 11, 2014, Pages 1174-1178

  Elleri, D ^a,b   Maltoni, G ^d   Allen, J M ^a,b   Nodale, M ^b   Kumareswaran, K ^b   Leelarathna, L ^b   Thabit, H ^b   Caldwell, K ^b   Wilinska, M E ^a,b   Calhoun, P ^c   Kollman, C ^c   Dunger, D B ^a,b   Hovorka, Roman ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b INSTITUTE OF METABOLIC SCIENCE   (United Kingdom)

^c JAEB CENTER FOR HEALTH RESEARCH   (United States)

^d NONE

Author keywords

Insulin delivery; Type 1 diabetes

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLOSED LOOP INSULIN DELIVERY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; MALE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; ALGORITHM; BLOOD; DIABETES MELLITUS, TYPE 1; MEAL; METABOLISM; TREATMENT OUTCOME;

ADOLESCENT; ALGORITHMS; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MEALS; TREATMENT OUTCOME;

EID: 84914151339     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12324     Document Type: Article

References (11)

1. Elleri D, Dunger DB, Hovorka R. Closed-loop insulin delivery for treatment of type 1 diabetes. BMC Med 2011; 120: 1-9.
2. Elleri D, Allen JM, Kumareswaran K et al. Closed-loop basal insulin delivery over 36 hours in adolescents with type 1 diabetes: randomized clinical trial. Diabetes Care 2013; 36: 838-844.
3. Diabetes Control and Complication Trial Study Group (DCCT). Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr 1994; 125: 177-188.
4. Burdick J, Chase HP, Slover RH et al. Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. Pediatrics 2004; 113: e221-224.
5. Olinder AL, Kernell A, Smide B. Missed bolus doses: devastating for metabolic control in CSII-treated adolescents with type 1 diabetes. Pediatr Diabetes 2009; 10: 142-148.
6. Vanderwel BW, Messer LH, Horton LA et al. Missed insulin boluses for snacks in youth with type 1 diabetes. Diabetes Care 2010; 33: 507-508.
7. Hovorka R, Allen JM, Elleri D et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 2010; 375: 743-751.
8. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes 2006; 55: 3344-3350.
9. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus sermautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008; 31: 934-939.
10. Bruttomesso D, Farret A, Costa S et al. Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: preliminary studies in Padova and Montpellier. J Diabetes Sci Technol 2009; 3: 1014-1021.
11. Calhoun P, Lum J, Beck RW, Kollman C. Performance comparison of the medtronic sof-sensor and enlite glucose sensors in inpatient studies of individuals with type 1 diabetes. Diabetes Technol Ther 2013; 15: 758-761.